Literature DB >> 20191037

Post-prandial lipid levels for assessing target goal achievement in type 2 diabetic patients taking statin.

Mikyung Kim1, Jihye Suk, Hyunjung Kim, Hyesuk Jung, Taeik Kim, Jeonghyun Park.   

Abstract

It is inconvenient to perform serum lipid analysis in fasting state in diabetic patients with drug treatment. In patients with statin treatment and Asian diet, it has not been clearly known whether non-fasting values could be used for the clinical decision making in diabetic patients. In this study, fasting and post-prandial plasma lipid profiles of hospitalized type 2 diabetic patients taking statin, were measured in whom standard diabetic breakfast in traditional Korean style were provided. In repeated-measures ANOVA, there were no significant differences among fasting, post-prandial 2 and 4 hr low-density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol values. When compared to fasting levels, both post-prandial 2 hr and 4 hr LDL cholesterol levels were misclassified as not achieved target goal only in 4% of patients. Post-prandial HDL cholesterol matched with fasting values in women, without exception. In conclusion, the fasting and post-prandial LDL and HDL cholesterol levels are not significantly different each other and can be used in the assessment of achieving target goal in type 2 diabetes taking statin after Korean diet.

Entities:  

Keywords:  Diabetes Mellitus, Type 2; Fasting; Korean Diet; Lipid Goal; Postprandial Period

Mesh:

Substances:

Year:  2010        PMID: 20191037      PMCID: PMC2826752          DOI: 10.3346/jkms.2010.25.3.387

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  26 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts).

Authors:  Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2003-08

3.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.

Authors: 
Journal:  Lancet       Date:  2001-03-31       Impact factor: 79.321

4.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28

5.  Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease.

Authors:  E J Schaefer; M C Audelin; J R McNamara; P K Shah; T Tayler; J A Daly; J L Augustin; L J Seman; J J Rubenstein
Journal:  Am J Cardiol       Date:  2001-11-15       Impact factor: 2.778

6.  The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  Robert Weiss; Melinda Harder; Jonathan Rowe
Journal:  Clin Ther       Date:  2003-05       Impact factor: 3.393

7.  Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.

Authors:  Søren S Lund; Lise Tarnow; Merete Frandsen; Ulla M Smidt; Oluf Pedersen; Hans-Henrik Parving; Allan A Vaag
Journal:  Eur J Endocrinol       Date:  2008-01       Impact factor: 6.664

8.  Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.

Authors:  Ernst J Schaefer; Judith R McNamara; Timothy Tayler; Jennifer A Daly; Joi A Gleason; Leo J Seman; Andrea Ferrari; Joel J Rubenstein
Journal:  Am J Cardiol       Date:  2002-10-01       Impact factor: 2.778

9.  Underidentification and undertreatment issues.

Authors:  Michael B Bottorff
Journal:  J Manag Care Pharm       Date:  2003 Jan-Feb

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.